Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Operating Leases (2020 - 2025)

Historic Operating Leases for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $2.0 million.

  • SAB Biotherapeutics' Operating Leases rose 19834.33% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 19834.33%. This contributed to the annual value of $581148.0 for FY2024, which is 859.25% down from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Operating Leases is $2.0 million, which was up 19834.33% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Operating Leases registered a high of $2.8 million during Q4 2021, and its lowest value of $361225.0 during Q4 2022.
  • Moreover, its 5-year median value for Operating Leases was $762775.0 (2022), whereas its average is $1.2 million.
  • Per our database at Business Quant, SAB Biotherapeutics' Operating Leases plummeted by 8707.88% in 2022 and then soared by 34490.78% in 2025.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Operating Leases stood at $2.8 million in 2021, then tumbled by 87.08% to $361225.0 in 2022, then skyrocketed by 76.01% to $635777.0 in 2023, then dropped by 8.59% to $581148.0 in 2024, then skyrocketed by 250.59% to $2.0 million in 2025.
  • Its Operating Leases was $2.0 million in Q3 2025, compared to $2.3 million in Q2 2025 and $2.5 million in Q1 2025.